Oligometastatic renal cell carcinoma: radiotherapy as a new standard of care?
[...]in a prospective analysis of 30 patients with 82 secondary renal cancer lesions, local control rate with SBRT was nearly 98%, with a median overall survival of 32 months.7 The number and size of metastatic lesions outside the field of radiation were shown to reduce due to the abscopal effect vi...
Gespeichert in:
| Veröffentlicht in: | The lancet oncology 2021-12, Vol.22 (12), p.1644-1645 |
|---|---|
| Hauptverfasser: | , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1645 |
|---|---|
| container_issue | 12 |
| container_start_page | 1644 |
| container_title | The lancet oncology |
| container_volume | 22 |
| creator | Magné, Nicolas Latorzeff, Igor |
| description | [...]in a prospective analysis of 30 patients with 82 secondary renal cancer lesions, local control rate with SBRT was nearly 98%, with a median overall survival of 32 months.7 The number and size of metastatic lesions outside the field of radiation were shown to reduce due to the abscopal effect via an immune response and the secretion of antitumour and antiangiogenic factors. [...]with the delivery of high doses per fraction, SBRT was a minimally invasive and effective treatment for metastatic renal cell carcinoma.8 The integration of SBRT into the holistic management of patients with oligometastatic renal cell carcinoma might have a positive effect on the systemic control of the disease by postponing the introduction of systemic treatments. Of note, the study by Tang and colleagues2 showed that the median time between SBRT and systemic treatment initiation was extended in patients treated on all metastatic sites without changing patients’ survival outcome.9 In case of extracranial metastases from renal cell carcinoma, SBRT was associated with a 90% overall response rate with no major toxicity. [...]the study by Tang and colleagues2 shows that renal cell carcinoma can no longer be considered as radioresistant due to the biological effect of SBRT in oligometastic renal cell carcinoma. |
| doi_str_mv | 10.1016/S1470-2045(21)00665-3 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_hal_p</sourceid><recordid>TN_cdi_hal_primary_oai_HAL_hal_03507607v1</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1470204521006653</els_id><sourcerecordid>2604390457</sourcerecordid><originalsourceid>FETCH-LOGICAL-c427t-b49f74626d6a1f77900d58a7d945ee0ba59728fb8e398acee6cd1b88633318683</originalsourceid><addsrcrecordid>eNqFkc1u1TAQhS1ERUvhEUCR2LSLUDv-DZuqqoAi3aqLwtqa2BPqKokvdm5R3x7npnTBho3HGn1n7DmHkHeMfmSUqbNbJjStGyrkScNOKVVK1vwFOSptUUthzMv9fUUOyeuc7yllmlH5ihxyYaRiXB6R65sh_IwjzpBnmIOrEk4wVA6HckByYYojfKoS-BDnO0ywfawgV1BN-LsqkslD8lXsFxjP35CDHoaMb5_qMfnx5fP3y6t6c_P12-XFpnai0XPdibbXQjXKK2C91i2lXhrQvhUSkXYgW92YvjPIWwMOUTnPOmMU55wZZfgxOV3n3sFgtymMkB5thGCvLjZ26VEuqVZUP7DCnqzsNsVfO8yzHUNe9oMJ4y7bRlHVcqG1LuiHf9D7uEvFjz0leFusXCi5Ui7FnBP2zz9g1C7Z2H02djHeNszus7G86N4_Td91I_pn1d8wCnC-AlisewiYbHYBJ4c-JHSz9TH854k_V0ybTw</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2604390457</pqid></control><display><type>article</type><title>Oligometastatic renal cell carcinoma: radiotherapy as a new standard of care?</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><source>ProQuest Central UK/Ireland</source><creator>Magné, Nicolas ; Latorzeff, Igor</creator><creatorcontrib>Magné, Nicolas ; Latorzeff, Igor</creatorcontrib><description>[...]in a prospective analysis of 30 patients with 82 secondary renal cancer lesions, local control rate with SBRT was nearly 98%, with a median overall survival of 32 months.7 The number and size of metastatic lesions outside the field of radiation were shown to reduce due to the abscopal effect via an immune response and the secretion of antitumour and antiangiogenic factors. [...]with the delivery of high doses per fraction, SBRT was a minimally invasive and effective treatment for metastatic renal cell carcinoma.8 The integration of SBRT into the holistic management of patients with oligometastatic renal cell carcinoma might have a positive effect on the systemic control of the disease by postponing the introduction of systemic treatments. Of note, the study by Tang and colleagues2 showed that the median time between SBRT and systemic treatment initiation was extended in patients treated on all metastatic sites without changing patients’ survival outcome.9 In case of extracranial metastases from renal cell carcinoma, SBRT was associated with a 90% overall response rate with no major toxicity. [...]the study by Tang and colleagues2 shows that renal cell carcinoma can no longer be considered as radioresistant due to the biological effect of SBRT in oligometastic renal cell carcinoma.</description><identifier>ISSN: 1470-2045</identifier><identifier>EISSN: 1474-5488</identifier><identifier>DOI: 10.1016/S1470-2045(21)00665-3</identifier><identifier>PMID: 34856135</identifier><language>eng</language><publisher>England: Elsevier Ltd</publisher><subject>Carcinoma, Renal Cell - radiotherapy ; Humans ; Immune response ; Immunotherapy ; Kidney cancer ; Kidney Neoplasms - radiotherapy ; Medical prognosis ; Metastases ; Metastasis ; Patients ; Physics ; Radiation Oncology ; Radiation therapy ; Radiosurgery ; Standard of Care ; Toxicity</subject><ispartof>The lancet oncology, 2021-12, Vol.22 (12), p.1644-1645</ispartof><rights>2021 Elsevier Ltd</rights><rights>2021. Elsevier Ltd</rights><rights>Distributed under a Creative Commons Attribution 4.0 International License</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c427t-b49f74626d6a1f77900d58a7d945ee0ba59728fb8e398acee6cd1b88633318683</citedby><cites>FETCH-LOGICAL-c427t-b49f74626d6a1f77900d58a7d945ee0ba59728fb8e398acee6cd1b88633318683</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.proquest.com/docview/2604390457?pq-origsite=primo$$EHTML$$P50$$Gproquest$$H</linktohtml><link.rule.ids>230,314,776,780,881,3536,27903,27904,64361,64363,64365,65309,72215</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/34856135$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttps://hal.science/hal-03507607$$DView record in HAL$$Hfree_for_read</backlink></links><search><creatorcontrib>Magné, Nicolas</creatorcontrib><creatorcontrib>Latorzeff, Igor</creatorcontrib><title>Oligometastatic renal cell carcinoma: radiotherapy as a new standard of care?</title><title>The lancet oncology</title><addtitle>Lancet Oncol</addtitle><description>[...]in a prospective analysis of 30 patients with 82 secondary renal cancer lesions, local control rate with SBRT was nearly 98%, with a median overall survival of 32 months.7 The number and size of metastatic lesions outside the field of radiation were shown to reduce due to the abscopal effect via an immune response and the secretion of antitumour and antiangiogenic factors. [...]with the delivery of high doses per fraction, SBRT was a minimally invasive and effective treatment for metastatic renal cell carcinoma.8 The integration of SBRT into the holistic management of patients with oligometastatic renal cell carcinoma might have a positive effect on the systemic control of the disease by postponing the introduction of systemic treatments. Of note, the study by Tang and colleagues2 showed that the median time between SBRT and systemic treatment initiation was extended in patients treated on all metastatic sites without changing patients’ survival outcome.9 In case of extracranial metastases from renal cell carcinoma, SBRT was associated with a 90% overall response rate with no major toxicity. [...]the study by Tang and colleagues2 shows that renal cell carcinoma can no longer be considered as radioresistant due to the biological effect of SBRT in oligometastic renal cell carcinoma.</description><subject>Carcinoma, Renal Cell - radiotherapy</subject><subject>Humans</subject><subject>Immune response</subject><subject>Immunotherapy</subject><subject>Kidney cancer</subject><subject>Kidney Neoplasms - radiotherapy</subject><subject>Medical prognosis</subject><subject>Metastases</subject><subject>Metastasis</subject><subject>Patients</subject><subject>Physics</subject><subject>Radiation Oncology</subject><subject>Radiation therapy</subject><subject>Radiosurgery</subject><subject>Standard of Care</subject><subject>Toxicity</subject><issn>1470-2045</issn><issn>1474-5488</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNqFkc1u1TAQhS1ERUvhEUCR2LSLUDv-DZuqqoAi3aqLwtqa2BPqKokvdm5R3x7npnTBho3HGn1n7DmHkHeMfmSUqbNbJjStGyrkScNOKVVK1vwFOSptUUthzMv9fUUOyeuc7yllmlH5ihxyYaRiXB6R65sh_IwjzpBnmIOrEk4wVA6HckByYYojfKoS-BDnO0ywfawgV1BN-LsqkslD8lXsFxjP35CDHoaMb5_qMfnx5fP3y6t6c_P12-XFpnai0XPdibbXQjXKK2C91i2lXhrQvhUSkXYgW92YvjPIWwMOUTnPOmMU55wZZfgxOV3n3sFgtymMkB5thGCvLjZ26VEuqVZUP7DCnqzsNsVfO8yzHUNe9oMJ4y7bRlHVcqG1LuiHf9D7uEvFjz0leFusXCi5Ui7FnBP2zz9g1C7Z2H02djHeNszus7G86N4_Td91I_pn1d8wCnC-AlisewiYbHYBJ4c-JHSz9TH854k_V0ybTw</recordid><startdate>20211201</startdate><enddate>20211201</enddate><creator>Magné, Nicolas</creator><creator>Latorzeff, Igor</creator><general>Elsevier Ltd</general><general>Elsevier Limited</general><general>Elsevier</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>0TZ</scope><scope>3V.</scope><scope>7RV</scope><scope>7TO</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8C2</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>H94</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M1P</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>1XC</scope></search><sort><creationdate>20211201</creationdate><title>Oligometastatic renal cell carcinoma: radiotherapy as a new standard of care?</title><author>Magné, Nicolas ; Latorzeff, Igor</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c427t-b49f74626d6a1f77900d58a7d945ee0ba59728fb8e398acee6cd1b88633318683</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Carcinoma, Renal Cell - radiotherapy</topic><topic>Humans</topic><topic>Immune response</topic><topic>Immunotherapy</topic><topic>Kidney cancer</topic><topic>Kidney Neoplasms - radiotherapy</topic><topic>Medical prognosis</topic><topic>Metastases</topic><topic>Metastasis</topic><topic>Patients</topic><topic>Physics</topic><topic>Radiation Oncology</topic><topic>Radiation therapy</topic><topic>Radiosurgery</topic><topic>Standard of Care</topic><topic>Toxicity</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Magné, Nicolas</creatorcontrib><creatorcontrib>Latorzeff, Igor</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Pharma and Biotech Premium PRO</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Lancet Titles</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>Hyper Article en Ligne (HAL)</collection><jtitle>The lancet oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Magné, Nicolas</au><au>Latorzeff, Igor</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Oligometastatic renal cell carcinoma: radiotherapy as a new standard of care?</atitle><jtitle>The lancet oncology</jtitle><addtitle>Lancet Oncol</addtitle><date>2021-12-01</date><risdate>2021</risdate><volume>22</volume><issue>12</issue><spage>1644</spage><epage>1645</epage><pages>1644-1645</pages><issn>1470-2045</issn><eissn>1474-5488</eissn><abstract>[...]in a prospective analysis of 30 patients with 82 secondary renal cancer lesions, local control rate with SBRT was nearly 98%, with a median overall survival of 32 months.7 The number and size of metastatic lesions outside the field of radiation were shown to reduce due to the abscopal effect via an immune response and the secretion of antitumour and antiangiogenic factors. [...]with the delivery of high doses per fraction, SBRT was a minimally invasive and effective treatment for metastatic renal cell carcinoma.8 The integration of SBRT into the holistic management of patients with oligometastatic renal cell carcinoma might have a positive effect on the systemic control of the disease by postponing the introduction of systemic treatments. Of note, the study by Tang and colleagues2 showed that the median time between SBRT and systemic treatment initiation was extended in patients treated on all metastatic sites without changing patients’ survival outcome.9 In case of extracranial metastases from renal cell carcinoma, SBRT was associated with a 90% overall response rate with no major toxicity. [...]the study by Tang and colleagues2 shows that renal cell carcinoma can no longer be considered as radioresistant due to the biological effect of SBRT in oligometastic renal cell carcinoma.</abstract><cop>England</cop><pub>Elsevier Ltd</pub><pmid>34856135</pmid><doi>10.1016/S1470-2045(21)00665-3</doi><tpages>2</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1470-2045 |
| ispartof | The lancet oncology, 2021-12, Vol.22 (12), p.1644-1645 |
| issn | 1470-2045 1474-5488 |
| language | eng |
| recordid | cdi_hal_primary_oai_HAL_hal_03507607v1 |
| source | MEDLINE; Elsevier ScienceDirect Journals; ProQuest Central UK/Ireland |
| subjects | Carcinoma, Renal Cell - radiotherapy Humans Immune response Immunotherapy Kidney cancer Kidney Neoplasms - radiotherapy Medical prognosis Metastases Metastasis Patients Physics Radiation Oncology Radiation therapy Radiosurgery Standard of Care Toxicity |
| title | Oligometastatic renal cell carcinoma: radiotherapy as a new standard of care? |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-24T01%3A39%3A28IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_hal_p&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Oligometastatic%20renal%20cell%20carcinoma:%20radiotherapy%20as%20a%20new%20standard%20of%20care?&rft.jtitle=The%20lancet%20oncology&rft.au=Magn%C3%A9,%20Nicolas&rft.date=2021-12-01&rft.volume=22&rft.issue=12&rft.spage=1644&rft.epage=1645&rft.pages=1644-1645&rft.issn=1470-2045&rft.eissn=1474-5488&rft_id=info:doi/10.1016/S1470-2045(21)00665-3&rft_dat=%3Cproquest_hal_p%3E2604390457%3C/proquest_hal_p%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2604390457&rft_id=info:pmid/34856135&rft_els_id=S1470204521006653&rfr_iscdi=true |